Cingulate (CING) News Today $3.87 +0.11 (+2.93%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Cingulate Inc. Reports Q2 2025 Financial ResultsAugust 20 at 3:50 AM | msn.comCingulate reports Q2 net loss ($4.8M) vs ($3.2M) last yearAugust 19 at 12:48 PM | msn.comCingulate Inc. Submits New Drug Application to FDA for CTx-1301, Anticipates Decision by Q4 2025August 19 at 8:51 AM | quiverquant.comQCingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent HighlightsAugust 19 at 8:45 AM | globenewswire.comCingulate puts CEO on leave days after second domestic battery arrestAugust 15, 2025 | bizjournals.comKC company puts CEO on leave days after second domestic battery arrestAugust 15, 2025 | msn.comCingulate places CEO Schaffer on administrative leaveAugust 15, 2025 | msn.comCingulate Chairman, CEO on Leave After Domestic Battery ChargeAugust 15, 2025 | marketwatch.comCingulate Inc. Delays Quarterly Report FilingAugust 15, 2025 | tipranks.comCingulate Inc. Appoints Jennifer Callahan as Interim CEO and Jay Roberts as Executive Chairman Amid Leadership TransitionAugust 15, 2025 | quiverquant.comQCingulate Inc CEO Shane Schaffer on Administrative LeaveAugust 15, 2025 | tipranks.comCingulate Provides Management Team UpdateAugust 15, 2025 | globenewswire.comCEO of KC-area pharma company faces domestic violence allegations - againAugust 12, 2025 | msn.comCingulate terminates COO one day after submitting drug for FDA approvalAugust 12, 2025 | bizjournals.comKC-area public company CEO faces felony charge for choking his girlfriendAugust 12, 2025 | bizjournals.comCingulate (CING) Projected to Post Earnings on TuesdayAugust 11, 2025 | americanbankingnews.comCingulate submits NDA for ADHD treatment to FDAAugust 8, 2025 | uk.investing.comCingulate Inc. (CING) - Yahoo FinanceAugust 8, 2025 | finance.yahoo.comSuperagers' Brains Are Different: Here's HowAugust 8, 2025 | msn.comCingulate Inc.’s Strategic Partnerships and NDA Submission Drive Buy RatingAugust 7, 2025 | tipranks.comCingulate Inc Submits NDA for ADHD TreatmentAugust 6, 2025 | tipranks.comCingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301August 6, 2025 | globenewswire.comCingulate gets $4.3M waiver, clearing way to submit for FDA approvalJuly 31, 2025 | bizjournals.comCingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301July 30, 2025 | finance.yahoo.comCingulate Inc. Receives Buy Rating: PDUFA Fee Waiver and Competitive Edge of CTx-1301 Boost Market ProspectsJuly 30, 2025 | tipranks.comIndividuals with alcohol use disorder have much higher concentration of glutathione in certain brain areasJuly 25, 2025 | msn.comCingulate Inc’s Recent Unregistered Equity Securities SalesJuly 25, 2025 | tipranks.comCingulate names Nilay Patel as chief legal officer ahead of FDA filingJuly 11, 2025 | uk.investing.comCingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug ApplicationJuly 9, 2025 | finance.yahoo.comCholine imbalance in the brain linked to with cognitive symptoms in young depression patientsJuly 9, 2025 | msn.comEfficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHDMay 21, 2025 | finance.yahoo.comCingulate Retail Buzz Surges As ADHD Drug Shows Phase 3 Pediatric EfficacyMay 21, 2025 | msn.comCingulate receives FDA meeting feedback on ADHD drugMay 16, 2025 | uk.investing.comCING: First Quarter 2025 ResultsMay 16, 2025 | finance.yahoo.comCingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD DrugMay 16, 2025 | msn.comFDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301May 14, 2025 | finance.yahoo.comCingulate Inc Terminates Grant Agreement with FoundationMay 13, 2025 | tipranks.comCingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety AssetsMay 8, 2025 | globenewswire.comRoth MKM Sticks to Their Buy Rating for Cingulate Inc (CING)May 3, 2025 | theglobeandmail.comWhy Some Humans Are More Likely to Help According to NeuroscienceMay 2, 2025 | msn.comType 2 diabetes alters brain circuits involved in reward processing, study findsMay 1, 2025 | msn.comCingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301April 30, 2025 | tipranks.comCingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHDApril 29, 2025 | finance.yahoo.comCING: 2024 Financial and Operational ResultsApril 10, 2025 | msn.comCingulate secures $3m to advance once-daily anxiety treatmentApril 10, 2025 | finance.yahoo.comCingulate receives $3M grant from to accelerate development of CTx-2103April 10, 2025 | markets.businessinsider.comCingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)April 9, 2025 | globenewswire.comRoth MKM Keeps Their Buy Rating on Cingulate Inc (CING)April 5, 2025 | markets.businessinsider.comCingulate completes pre-NDA meeting with FDA on NDA for CTx-1301April 4, 2025 | markets.businessinsider.comWhy Alzheimer's Risk Increases With This Common Condition: New StudyApril 2, 2025 | msn.com Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address CING Media Mentions By Week CING Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CING News Sentiment▼-0.220.47▲Average Medical News Sentiment CING News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CING Articles This Week▼142▲CING Articles Average Week Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunic News Today CervoMed News Today Oramed Pharmaceuticals News Today Quantum Biopharma News Today ESSA Pharma News Today Vaxart News Today Oncolytics Biotech News Today Alto Neuroscience News Today Entera Bio News Today Elutia News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CING) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWinning the AI WarWhat’s really driving the trade wars, reshoring, and sweeping executive orders? According to Porter Stansberry...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access